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Abstract   
A worldwide demographic shift is in progress and the aged population proportion is projected to more 
than double across the next four decades.  Our current healthcare models may not be adequate to handle 
this shift in demography, which may have serious consequences for the ageing population who are more 
prone to chronic diseases.  One proposed remediation is to provide in-home assisted healthcare with 
technology-intervened approaches.  Telemedicine, telehealth, e-health are paradigms found in scientific 
literature that provide clinical treatment through a technology intervention.  In evidence-based medical 
science, these technology interventions are evaluated through clinical trials, which are targeted to 
measure improvements in medical conditions and the treatment’s cost effectiveness.  However, 
effectiveness of a technology also depends on the interaction pattern between the technology and its’ 
users, especially the patients.  This paper presents (1) a meta-synthesis of clinical trials for technology-
intervened treatments of type 2 diabetes and (2) the Clinical User-Experience Evaluation (CUE).  CUE is 
a recommendation for future telemedicine clinical trials that focuses on the patient as the user from 
Human-Computer Interaction (HCI) perspective and was developed as part of this research.  The clinical 
trials reviewed were interpreted from a technology perspective and the non-medical or non-biological 
improvements of the users (patients) rather than the medical outcome.  Results show that technology-
intervened treatments provide positive behavior changes among patients and are potentially highly 
beneficial for chronic illness management such as type 2 diabetes.  The results from the CUE method 
show how it complements clinical trials to capture patients’ interaction with a technology.  
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experience evaluation. 
  
 1. Introduction  
The next four decades will see a demographic shift in the aged population where older generations retire 
while the proportion of working population comparatively decreases, sometimes termed a demographic 
time-bomb.  Chronic illnesses such as diabetes, heart disease, Chronic Obtrusive Pulmonary Disease 
(COPD), obesity, etc. are more common in the ageing so hospital visits will increase accordingly [1].  
This change in demography will negatively impact the patient/doctor, patient/nurse and patient to hospital 
bed ratios, which will consequently increase the overall costs of healthcare for society, possibly to 
unsustainable levels [2].   
Type 2 diabetes is a chronic disease that continues to grow worldwide, constantly increasing the 
demand on future healthcare systems.  This disease needs close monitoring and long-term management to 
prevent complications and expensive medical interventions, or even fatality [3].  Intensive management of 
blood glucose levels has been proven to reduce complications in both type 1 and type 2 diabetes [4].  
However, the demographic shift, rising healthcare costs, health complications associated with type 2 
diabetes and the cost of treatments raise concern about effective ways to manage the illness.   
Technology-intervened treatments present one possible way to provide care for type 2 diabetes 
patients.  Technology-intervened treatments have been used mostly for chronic illnesses such as 
cardiopulmonary disease, asthma and heart failure and are now increasingly used for diabetes monitoring 
[5].  In the medical literature, the technology-intervened treatments are referred as telemedicine, 
telehealth, telemonitoring, telecare and e-health.   
Currently, the benefits of technology-intervened treatments of diabetes, such as telemedicine, are 
investigated and presented based on the results obtained from clinical trials.  The focus of these clinical 
trials is to compare blood glucose and other medical conditions at the beginning with the results.  In the 
literature, the trials are concluded to be effective based on evidence of the improvement in the medical 
condition only and not the combination of technology applied in the treatment.  Importantly, patients must 
interact with the technology, which strongly determines the effectiveness of the treatment.  However, if 
there are interaction barriers patients may have with a technology they are not reported, which indicates 
the results on the degree of effectiveness are incomplete.  This information is important for future clinical 
trials in technology-intervened treatments that should also investigate the Human-Computer Interaction 
(HCI) between the patient and the technology.   
This paper is a meta-synthesis that systematically reviews the use of technology from the 
patient’s perspective with a focus on Human Computer Interaction (HCI) and not the medical outcomes.  
Meta-synthesis generally refers to examination and synthesis of findings, across multiple reports to 
explore new interpretations [6].  Information was collected from a comprehensive list of clinical trials 
conducted on type 2 diabetes that applied technology-intervened treatments for comparison and analysis.  
Notably, the focus is on the patient as the user in a HCI environment, where information is gathered about 
the non-medical conditions of improvement and influence of telemedicine on patient’s behavior, rather 
than medical results.  This study examines the results of clinical trials, which are interpreted from a 
technology perspective and the non-medical or non-biological improvements of the users (NB. the terms 
“user”, “patient” and “participant” are used interchangeably in the context of this paper).  The results 
imply technology-intervened treatments would highly benefit chronic disease management as every trial 
reviewed recorded significant behavior changes among patients linking persuasive technology and current 
telemedicine.  A Clinical User-Experience Evaluation (CUE) was developed based on the results of the 
meta-synthesis that proposes a recommendation for future investigations and/or clinical trials of 
technology-intervened treatments. 
This paper is organized as follows: section 2 provides background information on the 
management of type 2 diabetes and the technologies involved in technology-intervened treatments; 
section 3 provides the methodology applied in the meta-synthesis of literature; section 4 presents the 
outcome of the meta-synthesis; section 5 describes the CUE and its use in a clinical trial as a 
recommendation for future trials; section 6 provides a discussion of findings and section 7 concludes the 
paper. 
 2. Background 
2.1. The demographic shift 
Four challenges may arise from the increase in the ageing population: the demand for healthcare; the 
retired population versus working population ratio; the patient versus available healthcare ratio; and 
healthcare costs.  The current ageing population in the United States is approximately 8%, which is 
expected to rise to 17% by the year 2050 [7].  In contrast, Australia’s aged population will rise from 13% 
to 25% by 2056 [8].  The first challenge, the demand on healthcare, will occur because the ageing 
population is more prone to chronic diseases, which require higher levels of medical care.  The second 
challenge, the retired population/working population ratio, will adversely influence the government’s 
economic and financial plans.  The third challenge, the patient/healthcare ratio, is the demographic shift 
toward an aged population that will negatively influence the patient/doctor, patient/nurse and 
patient/hospital bed ratios, which will decrease available healthcare.  Finally, as the demand increases, 
healthcare costs will continue to rise and eventually become unfeasible. 
2.2. Diabetes types and economic cost 
Type 2 diabetes is one of the most dangerous chronic diseases that cause serious complications in elderly 
patients.  Although younger populations of first world countries are at risk, the prevalence of type 2 
diabetes is now increasing in older populations at alarming rates, which poses a growing threat for the 
future well-being of the projected aged population.   
Healthcare systems have struggled with the overwhelming number of patients suffering from 
diabetes [9].  Diabetes is one of the most dangerous widespread chronic diseases that create serious 
complications that can lead to additional disease states.  In 2000, medical studies projected the total 
number of people to suffer from diabetes would rise from 171 million in 2000 to 366 million in 2030 
worldwide [10].  However, current figures show this increase reached the earlier predicted figures in only 
ten years.  In fact, as at 2012, approximately 371 million people worldwide already have diabetes, a total 
of 4.8 million deaths were due to diabetes and treatment costs were approximately 471 billion dollars [9].  
This significant increase is attributed to the demographic shift in the proportion of people over 64 years of 
age [11] where 2.5 million of the diabetes related deaths were from the 60 to 79 age group [9].    
There are two forms of diabetes: type 1 and type 2.  Type 1 diabetes causes the pancreas to cease 
producing insulin.  Without insulin, the body’s cells cannot regulate glucose (sugar) uptake into cells and 
the body burns its own fats as a substitute, which is potentially life threatening if not treated [12].  
Patients with type 1 diabetes accumulate dangerous chemical substances in their blood from the burning 
of fat if not treated with daily injections of insulin.  Type 2 diabetes is more common than type 1 and is 
the most common chronic illness that threatens the well-being of the ageing population.  Type 2 diabetes 
affects 85-90% of all people with diabetes [12].  While it usually affects older adults, younger people, 
even children, are now developing type 2 diabetes.  The pancreas makes some insulin in type 2 diabetes 
patients but the body essentially develops immunity to insulin and the amounts produced are not enough 
to regulate blood glucose.  This affliction can initially be managed with healthy eating and regular 
physical activity but over time, many patients also need medication or insulin injection.   
There is currently no cure for type 2 diabetes so the recommended treatment is day to day 
management [12].  Type 2 diabetes treatments involve diet control, exercise, home blood glucose testing, 
and in some cases, oral medication with or without insulin.  Effective individualized treatments may also 
incorporate psychosocial, lifestyle and other medical interventions [13].  Diabetes needs strict control of 
the blood glucose level by balancing within a triangle known as the diabetes triangle (Figure 1), which 
consists of food, exercise and insulin (or medication) as the three corners [14].  Patients’ decisions sway 
in this triangle during their daily activities and if there is an imbalance, fluctuations in glucose level occur 
[15].  These fluctuations in the blood can cause hypoglycemia, a lack of blood sugar, or hyperglycemia, 
which is an excessive blood sugar ratio.  Both hypoglycemia and hyperglycemia are acute conditions 
because they can cause physical and psychological effects that could range from mild to life threatening.  
Education, awareness and involvement of patients can help to prevent potential effects [16]. 
 According to Zhang et al. [17], the total annual global health expenditure for diabetes in 2010 
was estimated to fall between $376.0 billion USD and $672.2 billion USD.  This accounted for 12% of 
the world’s total health expenditure.  In 2010, the global average expenditure related to diabetes per 
capita was $1330.00 USD [17]. Significantly, the economic cost of diabetes varies in different parts of the 
world.  For example, in Bangladesh, the cost of one diabetic patient for one year is $28 USD, in China 
$193 USD compared to the high costs of $8,478 USD cost in the United States and Norway $9,208 USD 
[9].  Notably, the treatment quality differs vastly depending on the country’s healthcare system.  
2.3. Technology-intervened treatments: Telemedicine, telehealth and 
e-health 
Technologies that are applied in health services and medicine go through a process known as Health 
Technology Assessment (HTA), which consists of: 
 The product life cycle;  
 The quality standards and regulations;  
 Evidence Based Practice (EBP);  
 Reimbursement processes; and  
 Other HTA processes that are regulated by national HTA bodies such as the Food and Drug 
Administration (FDA), USA, the National Health Service (NHS), UK, etc.  
To provide evidence for EBP, the technologies need to go through rigorous testing methods to 
prove their efficacy, which is done through clinical trials.  Clinical trials are formal procedures that are 
followed during drug development to check safety and efficacy, which refers to the "capacity of a 
beneficial effect", and data for health intervention (drugs, devices etc.).  Medical practitioners follow 
EBPs that aim to find best available evidence from medical science literature before a treatment decision 
is made by a clinician [18].  EBP supports the clinician in their decision on the risk and beneficial factors 
of a treatment for a particular patient [19,20].   
"Telemedicine" was introduced in the 1920s [21] but not initially used until the 1970s [22].  
Telemedicine is the use of Information and Communications Technology (ICT) to provide clinical 
treatments over distances [23].  Rapid development in ICT has contributed to the growth in telemedicine 
initiatives, which continues to evolve.  There is now a wide range of communication technologies 
available for telemedicine [24-26].  For example, after [23]collecting 104 peer reviewed definitions of 
telemedicine, Sood et al. [23] determined:  
“Telemedicine being a subset of telehealth, uses communications networks for delivery 
of healthcare services and medical education from one geographical location to another, 
primarily to address challenges like uneven distribution and shortage of infrastructural 
and human resources.”   
"Telehealth" is defined by the American Telemedicine Association (ATA) as closely associated 
with telemedicine but also encompasses a broader range of remote healthcare methods not always 
Food
InsulinPhysical Actiivty
 
Figure 1 The diabetes triangle: clinical model of diabetes management. In real this model behaves 
more plastic and dynamic than the triangle shape envisages [15]. 
 involved in clinical services.  These technological methods include videoconferencing, still image 
transmission of, e-health including patient portals, remote monitoring of vital signs, continuing medical 
education and nursing call centers [27]. 
The term "e-health" emerged with the growth of the Web and can be viewed as a type of e-
commerce [28].  According to Eysenbach [28], e-health was used more by industry and commerce people 
than academics and was created to be aligned with other “e” words such as e-commerce, e-business, e-
solutions etc.  His definition is:  
“e-health is an emerging field in the intersection of medical informatics, public health 
and business, referring to health services and information delivered or enhanced 
through the Internet and related technologies.  In a broader sense, the term 
characterizes not only a technical development, but also a state-of-mind, a way of 
thinking, an attitude, and a commitment for networked, global thinking, to improve 
health care locally, regionally, and worldwide by using information and communication 
technology” [28]. 
2.4. Human Computer Interaction (HCI) 
Computer systems are developed through a User-Centered Design (UCD) in HCI as opposed to the 
traditional software engineering and computer science approach where the technologies or functionality 
are the initial concentration.  UCD keeps the human users and their goals central to design and evaluation 
[29].   
Qualitative research methods, which are common practice in HCI, aim to generate richer 
knowledge about users.  According to Boulding (1956), “knowledge does not grow in abstract and 
knowledge does not exist by itself, it is a property of interaction between agents and the environment and 
is tied to perspectives, intentions and perceptions”.  A message may have a meaning but the meaning 
depends on the code or set of alternatives from which the message has originated [30].  Qualitative 
research has been used by Dalcher [31] to understand major ICT and Information System (IS) failures in 
the United States.  Dalcher [31] practices qualitative research in software engineering processes and 
argues that “knowledge is deeply bound to its original context and thus enables for a contextually 
correct understanding”.  Effective capturing of a precise context is the only way to discover information 
about the informer´s position, perspective and relationship with the environment.  To understand IS 
failures, Dalcher urges that any useful information must therefore be accompanied by additional 
contextual information that will shed light on its utility, validity and relevance and any methods adopted 
need to identify such contextual knowledge [31,32].   
HCI techniques have many methods of evaluation, some are analytical and focus on the system 
with a set criteria while others are empirical and involve people using the system.  Contextual design, 
interviews, observations, participatory design, ethnography are effective techniques in performing 
empirical evaluations.  HCI mandates anyone who uses a system be classed as a user, so transcending the 
HCI empirical evaluation methods to technology-intervened treatments, the “user” classification includes 
doctors, nurses, care providers as well as the patients.  This paper focuses predominantly on patients as 
the most important users because their well-being depends on the proper use of the technology.  Patients’ 
feelings, comfort, partiality, ease of use are very important factors to gauge the success rate of a 
technology.  This paper focuses on the patients’ perspective and the non-medical factors of improvement 
through telemedicine, telehealth and e-health for the treatment of type 2 diabetes.   
2.5. Comparison with Related Works 
Ekeland et al. [33] established that besides the traditional questions of clinical benefits and the cost-
efficiency of telemedicine, there are "new questions rising in telemedicine".  There are a resurgence of 
new questions arising in telemedicine such as patients’ perspectives and ongoing collaborative 
achievements.  Ekeland et al. [33] performed a systematic review of other reviews in telemedicine, which 
provided a strong direction to show the effectiveness of telemedicine for different illnesses in general.  
Methodologies of the clinical trials of telemedicine are heterogeneous, which makes comparisons of 
different systematic reviews difficult.  However, evidence of an aspect of telemedicine (e.g., effectiveness 
 on patients or cost efficiency) is built through systematic reviews of clinical trials.  These reviews support 
the EBP for medical science.  
Verhoeven et al. [34] and Verhoeven et al. [35] presents a diabetes-specific systematic review of 
telemedicine from technology perspective. Both of Verhoeven et al’s reviews thoroughly explored the 
technologies for diabetes care in general and concluded that telemedicine is practical, cost-effective and 
reliable.  The authors found that clinical, behavioral and care coordinator outcomes provided a strong 
basis of data on technology intervened treatments of telemedicine and diabetes.  
This paper extends and expands the above works and the approach differs in three ways: 
1) This paper separates type 2 diabetes technologies from other types of diabetes.  Verhoeven 
et al. [34] and Verhoeven et al. [35] included diabetes types (i.e., type 1, type 2 and 
gestational diabetes).  However, the daily management and effects on the patient differ 
depending on which type.  Gestational diabetes occurs among women during pregnancy and 
if untreated may cause serious health problems and future diabetes risks to both the mother 
and child.  Type 1 diabetes is fatal; the patient needs to take an insulin dosage to stay alive.  
Type 1 diabetes is prevalent in the population younger than 40 and often known as "juvenile 
diabetes".  In contrast, type 2 diabetes is not fatal during the initial stages and with proper 
management the patient can enjoy a normal and healthy life.  Due to the differences in types 
of diabetes, the technology interventions differ in the urgency and interaction patterns for 
the varied types of diabetes.   
2) This paper proposes a method, Clinical User-Experience Evaluation (CUE) to capture 
individual patient perspectives.  The CUE aims to expand and explore the findings of 
Verhoeven et al. [34] and Verhoeven et al. [35] who stated some patients benefited more 
than others.  This paper proposes the method CUE, which will help to further understand 
these reasons in detail to better inform research in persuasive technology that finds one 
design does not fit all [36,37]; 
3) Verhoeven et al. [34] and Verhoeven et al. [35] noted that patients found the technology too 
complex, costly and time consuming with some patients needed greater assistance with self-
care than they received in the intervention settings.  In these ICT-based care cases, online 
training and personal assistance might be necessary and this paper extends from that to 
provide analysis in two criteria: 
a. The degree of setup, maintenance and training; and 
b. Patient withdrawals.  
The CUE methodology is aimed to unpack the variations in outcome of individual patients 
using the technology. 
2.6. Persuasive technologies and the diabetes triangle 
Persuasive technology is a type of technology that is intentionally designed in a way to change a person’s 
attitude or behavior[38].  Alternately, these technologies are also referred to as Behavior Change Support 
Systems (BCSS) due to the support provided to an individual to make behavioral changes[39].  The use of 
force (coercion) or misinformation (deception) is outside of the scope of persuasive technology because 
persuasion is a voluntary change of behavior or attitude or both.  Just-in-time persuasive interfaces can be 
created to motivate behavior change [40].  Several frameworks exist for designing  [41] and evaluating 
[42,43] persuasive technology interventions.  For example, Intille [44] reviewed that there are four 
components to effective just-in-time information that include: 
1) A simple, tailored message that is easy to understand; 
2) The message occurs at an appropriate time; 
3) The message is given at an appropriate place; and  
4) The message uses a non-irritating strategy [45].   
Evidence of effectiveness of persuasive technology to control behavior about food and exercise 
started approximately two decades ago.  An example of persuasive technologies for better eating habits is 
the USA's Food and Drug Administration (FDA) successful recommendation for eating fruits and 
vegetables.  They promoted better habits via the “5-A-Day Adventures” multimedia application produced 
on CD-ROM by Dole Food Corp [46].  This “edutainment” application uses animated characters, music, 
 and games to encourage children to eat the number of daily servings of fruits and vegetables.  Examples 
of persuasive technologies for better exercise habits include  
 Nintendo’s Pocket Pikachu with pedometer is designed to persuade children to do more 
physical activities consistently [47].  The pet that lives inside the device requires the owner 
to walk, run, or jump each day to keep the pet alive.  This persuasion was very effective due 
to the popularity the Pokémon animation series and children’s affinity with the characters; 
and  
 Nike’s “Fuelband” is an all-day activity monitor/pedometer bracelet that tracks total daily 
steps and reward a person for being active based on a goal known as “NikeFuel” goal. 
3. Research objectives and rationale 
Medical science practitioners and healthcare professionals conduct the clinical trials that gather evidence 
on efficacy and cost-effectiveness of telemedicine interventions.  The evidence that is gathered from 
clinical trials in medical science is through a systematic review for EBP.  These systematic reviews aim to 
ask one (and sometimes more) specific question(s) to gather all supporting evidence from the answer(s).   
This paper adopts an approach similar to a systematic review that uses a keyword search to 
choose papers to review the effectiveness of clinical trials for type 2 diabetes.  Evidence in diabetes 
research shows that intensive treatment with frequent monitoring of the blood glucose helps to reduce 
further complications.  There are many cases in the literature of clinical trials that examined the use of 
telemedicine for diabetes treatments to determine the efficacy of such treatments.  However, new 
technologies emerge so rapidly there are many that have not yet been evaluated in clinical trials and 
without these formal evaluations will never be used in common practice.  Because this paper reviews past 
clinical trials of telemedicine treatments for type 2 diabetes patients, the focus is on the technologies that 
have been assessed in a clinical trial and not new technologies.   
This study is carried out from the perspective HCI because there are significant differences 
between a drug treatment and a technology treatment, such as telemedicine.  The scope of telemedicine 
technologies is non-pharmacological, non-immunological and non-biological.  Instead, the capability of 
usage is important because results may vary depending on the technological skills of the patients.  In 
many cases, some training is required with technology-intervened treatments to ensure patient’s capability 
and engagement.  Contrarily, there are no training required with a drug and their effects are at the 
pharmacological, immunological and metabolic levels.  Because the user has frequent or regular 
interaction with the technologies, especially in the case of type 2 diabetes interventions, the feelings of 
these users towards the technologies are almost as important to successful outcomes as the drug 
treatments.  
3.1. Research questions 
Technology-intervened treatments fall into two domains; the domain of medical science for their 
utilization in healthcare and the domain of IT for the technology design and user evaluation.  The term 
“user” in telemedicine would refer to doctors, nurses, patients, caregivers who all use the technology and 
make up the user group.  However, only the patients use telemedicine methods as a form of treatment for 
life altering illnesses, all others use the technologies for the purpose of job requirements.  Therefore, 
throughout the rest of this paper the term “user(s)” are referring to patients.  The following two questions 
were the focus of this review: 
1) How effective have telemedicine services been for the treatment of type 2 diabetes?; and 
2) What improvements did telemedicine provide for type 2 diabetes patients from technology 
use perspective? 
3.2. Methodology of the meta-synthesis 
The methodology of the meta-synthesis involved a systematic review that comprised of four iterative 
steps (Figure 2): 
 Step 1 - Literature search - Pubmed, Science Direct and Google scholar were the databases used to 
search for literature on clinical trials of type 2 diabetes telemedicine.  No limits were posed on sample 
population size, intervention type and clinical trial design.  The search keywords used were - “type 2 
diabetes”, “clinical trial”, “telemedicine”, “ehealth”, “telehealth”, “telecare”, “telemonitoring”, 
“technology”. 
Step 2 - Intervention types - All variations of technology intervention for diabetes type 2 treatments were 
included with no limits on the type of technology. 
Step 3 - Content Extraction - Each paper was analyzed systematically in the following order:  
1) Methodology;  
2) Conclusion;  
3) Discussion; and   
4) Results.  
The contents extracted from the literature (Appendix A) included: 
 The type of diabetes (type1 and/or 2); 
 The behavioral outcomes;  
 The patient dropouts;  
 The type of technology used;  
 The contents about patients’ non-medical conditions;  
 The patients’ feelings comments about the technology; and  
 The patients’ difficulty or ease with the technology.  
Notably, not all papers contained contents of the above bullet list.   
Step 4 – Exclusion criteria – Because search results most often yielded type 1 diabetes, clinical trial 
design and clinical trial planning for telemedicine, the following exclusion criteria were used to filter the 
results (Figure 2): 
Criteria 1)   Papers that were about ICT and diabetes-care but were not clinical trials were excluded 
since this is not a review of the available technology; 
Criteria 2)   Only papers on type 2 diabetes were included.  Papers on telemedicine clinical trials on 
type 1 diabetes were excluded.  However, papers that considered both types 1 and 2 diabetes 
patients were included but only information on type 2 diabetes were analyzed; 
Criteria 3)   Papers that only published the plan, proposal or study design of a clinical trial that has 
not yet commenced were excluded; and 
 
Figure 2  Methodology of paper selection for the meta-synthesis 
 Criteria 4)   Papers that were published in languages other language than English were also 
excluded from this review.   
A number of prominent diabetes clinical trials were excluded from this meta-synthesis because 
they did not align with one or more of the criteria (Figure 2).  For example, the vast French IDEATEL 
diabetes project [48-50] and the telemedicine clinical trial of diabetes conducted by Leichter et al. [51], 
[52] and Shultz et al. [53] were excluded because they all incorporated both type 1 and type 2 diabetes.  
Studies by McFarland et al. [54], Stone et al. [55], Estrada et al. [56] and Rodriguez-Idigoras et al. [57] 
did not report anything about dropout numbers, reasons for dropout and behavioral changes but only 
presented data of medical conditions improvements.  Other exclusions included, for example, Watson et 
al. [58] who presents a pilot study, Eakin et al. [59] who presents a preliminary trial plan and Davis et al. 
[60] who presents the technology used at a remote clinic for low-income community.  Figure 2 presents 
the workflow used in the paper selection process and the number of actual papers excluded and included.   
4. The meta-synthesis findings and discussion 
Nineteen clinical trials of technology intervened treatments of type 2 diabetes were selected to be 
included in the meta-synthesis based on the methodology described in section 3.3.  Five criteria were used 
to review the selected trials shown in Appendix A, which include: 
Criteria 1)   The technology type;  
Criteria 2)   The degree of setup, maintenance and training;  
Criteria 3)   Patient withdrawals;  
Criteria 4)   The effectiveness of the telemedicine; and 
Criteria 5)   The behavioral improvements.   
4.1. Technology type 
Figure 3 presents a classification diagram of telemedicine technology that has been used in a clinical trial 
for type 2 diabetes.  The technologies range from uncomplicated, where patients and clinicians 
communicate through phone, email or SMS (short message service), to complex web based frameworks 
that require connection to the Internet.  The different technology categories include:  
 Handheld portable devices - devices that are easy for the patient to carry and automatically 
record time, date and blood glucose levels [61,62].  For example, sample recommendations 
such as "Please, decrease the long acting insulin by two units", "Please add one tablet of 
sulfonylurea in the evening", "Lack of exercise may be the cause of the aggravated glucose 
level" and "Your glucose control seems to be good" etc., can be sent using the mobile phone 
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Figure 3  Classification of the clinical trials of telemedicine for diabetes type 2 based on technology 
 SMS service [63]; 
 Transfer of data via modem followed by telephone counseling - methods used in earlier 
periods before the Internet was widely available [64];   
 Automated Telephone Disease Management (ATDM) – a telephone-based system where 
patients receive calls at predetermined times and listen to self-management tips navigated 
via the telephone keypad [65] and the modern version where phone calls are automated to 
emulate the conversation with a physician [66];  
 Glucometer modem transfer followed by graphical report generation [53] ; 
 Data entry of touch tone telephone followed by voice message from clinicians [67]; 
 Interactive programs on CD Rom to educate on self-management [68]; 
 Web-based programs on self-management including chat room forums to enlist strangers as 
supporters [69] the iCare Desktop, the Health Buddy appliance web interfaces [70], web-
based diabetes management systems [71] and the Internet Based Glucose Monitoring 
System (IBGMS) [72],;  
 Teleconferencing - a person to person connection via telephone [73]; and  
 Pro-active call center treatment support - a telephone-based system where conversation is 
not automatic like the ATDM.  The conversation takes place with trained non-medical 
operators [74] 
4.2. Training, setup and maintenance of the clinical trial technologies 
To determine the success or failure of technology development, understanding users’ needs is important 
[75].  Bardram [76] stated that “the clinical benefit of a healthcare technology might be diluted 
significantly if the patients find the technology hard to use”.  System complexity and poorly crafted 
interfaces can cause negative emotional responses in the user, which lead to experiences of confusion, 
frustration, and failure [77].  Further, errors can be frustrating experiences for novice users who are 
unable to fully understand its cause.  In fact, if a user is unable to understand how to appropriately 
respond to an error, they may perform actions that compound its severity, which invariably compounds 
feelings of frustration [78,79].   
User training can help to alleviate errors made by users and to help them to understand the 
system.  Ideally, patients should have the knowledge to operate the technology in the appropriate way.  
However, technology skills vary and patients that fail to use the technology efficiently often experience 
dissatisfaction, which can ultimately cause the patients to not engage in the treatment and indirectly 
hamper medical improvements.  For this reason, most clinical trials provide a training and instruction 
manual on how to use the technology.  Notably, the trials reviewed in this paper did not all report the 
specifics of the technology training applied for the study.  Tsang et al. [62] investigated technical issues 
of patients in their trial.  Bujnowska-Fedak et al. [80] found that patients did not find the technology in 
their trial to be intuitive enough; only 35% of patients could use the technology alone, 24% required 
family support and 41% were unable to use the system and required constant family assistance.  The 
results found that patients who operated the equipment by themselves benefited more than those that 
could not or those that required assistance, which shows the importance of investigations of the 
technology from the HCI (albeit the patients’) perspective.  Appendix A presents a summary about 
technology training, setup, maintenance issues of the reviewed trials.   
Users often respond to technology as if the device were another person in a social context [81].  
An experiment on the "rule of reciprocity" was demonstrated where users were happier to provide helping 
behavior to a computer that had assisted helped them previously than to a different computer [40].  
Further laboratory experiments examined how users are susceptible to flattery from computers and this 
flattery has the same effects as if given by a human [45].   
Important functions in telemedicine are the setup and maintenance of the devices in the users’ 
home because patients should not be expected to have this knowledge.  Generally, technical support is 
usually provided to assist with these functions as well as troubleshooting any technological problems that 
arise.  Problems and negative experiences can alter a user’s trust in a technology.  These results show that 
if patients have to troubleshoot the telemedicine technology, the effectiveness of the treatment can 
decrease indirectly as users (patients) stop using the technology due to frustration.  Because the focus was 
 predominantly on the medical data and not the technology used, the majority of clinical trials reviewed, 
did not report any technical problems or maintenance information.  Yet one study by Faridi et al. [82] 
reported that the technology barrier, which was the difficulty of using a mobile phone, had caused lack of 
adherence to a mobile phone based system.   
4.3. Participant withdrawal and/or dropouts 
The reasons for participant withdrawal, shown in Appendix A, were not reported in the majority of the 
nineteen reviewed trials reviewed.  There were two withdrawals reported by Rutten et al. [61] due to lack 
of motivation to adhere to the self-monitoring.  The studies by Lavery et al.[83], Cherry et al. [70] and 
Biermann et al. [64] did not report any dropouts.  Izquierdo et al.[73] reported several patients who did 
not send the data in time so were withdrawn by default.  There were a large number of dropouts in the 
following studies: 10 by Shultz et al. [53], 43 by Glasgow and Toobert [68] and 37 by McKay et al. [69], 
but the reasons were not reported.  Williams et al. [66] found four dropouts from 60 patients, due to 
patients’ inability to use the blood glucose meter and disappointment with the intervention.  The study by 
Meneghini et al. [67], which had 77 withdrawals, was the only one that posed the question for future 
research to investigate reasons for not using the system in the trial.  
The lack of data about withdrawal and/or dropouts led to three assumptions:  
1) The reasons were not investigated;  
2) The reasons were investigated but not published; or  
3) The reasons were out of the scope of the clinical trials.  
Based on these assumptions, the authors of the reviewed clinical trials were emailed and responses were 
received from three.  Two authors stated that withdrawal reasons were not recorded.  However, one stated 
although the reasons for withdrawals were not in the research scope, they were discussed and provided 
information about patient behavior for this analysis.   
The study by Young et al. [74] recorded and published the reasons for dropout and withdrawal.  
There were 83 dropouts in the intervention group with an additional 22 for call center–related reasons.  
The reasons reported included: eight participants were not able to cope with the calls; four participants 
were unhappy with the advice given; three due to the travel required; three changed their minds; and two 
were too busy to use the intervention. 
The tendency for participants to withdraw from a trial would be of great interest from the ICT 
and HCI perspective.  Some patients possibly dropout or withdraw (unless for medical reasons) due to the 
technology involved.  The reasons could be found to relate to usage and interaction issues such as 
difficulty of use, technical problems, the complexity higher than the patients’ skill level and/or the 
patients’ confidence level in, and willingness to adopt, a technology.  For example, a publication by 
Steele et al. [84], proposed that patients’ willingness to adopt a technology-intervened treatment could be 
influenced by independence, perceived improvement in life and ease of use.  All participants believed that 
independence is of paramount importance to them and they would prefer to remain home and use 
technology rather than being in a nursing home.  If benefits of the technology were explained to the 
participants most of them had shown willingness to adopt the technology even though they had concerns 
about change of lifestyle due to its use.  Participants commented that they would consider using the 
system if it is deemed useful, reliable and provides benefits to their current lifestyle.  Each participant had 
different levels of skills to use the technology but they stated that the ease of use was one factor of 
choosing the technology.  Participants mentioned that availability of training, the available quality of 
support for training would let them use the technology if it was not easy to use.  
Patients’ withdrawal from clinical trials is common in most clinical trials [85].  Jadad [85] 
presented a scale that independently assesses the quality of methodology of a clinical trial.  The Jadad 
Scale, also known as the Oxford Quality Scoring System, shows the importance of quantifying the 
number of withdrawals and dropouts in a clinical trial to assess the effectiveness of the employed 
methodology [86].  Notably, the reasons for patient withdrawals are often not collected or published even 
though the number of withdrawals affects the outputs and statistics of the clinical trial.  This practice is 
 common because the objective of the clinical trials is to find out improvements in particular medical 
conditions and cost effectiveness of a telemedicine.  However, to create sustainable telemedicine practice, 
data on withdrawals are significantly important in understanding the reasons why patients dropout and 
especially if caused by the technology.   
4.4. Effectiveness of telemedicine for type 2 diabetes patients 
The clinical trial results were used to assess the effectiveness of telemedicine for type 2 diabetes patients.  
Most of the reviewed papers are randomized clinical trials where the blood glucose is measured initially 
as a baseline and then measured after a certain period after the intervention.  The baseline and post-
intervention results are then compared between control groups. 
This review relied solely on the publications about the clinical trials to extract information, 
regardless of the specific applied design method so only available results and conclusions were assessed 
about the effectiveness of telemedicine treatment.  Surprisingly, the results were mixed where not all 
trials agreed that telemedicine for type 2 diabetes treatment was effective.  Our results are consistent with 
the results from [33] who conducted a systematic review of reviews on the impacts and costs of 
telemedicine service.  They found that out of eighty heterogeneous reviewed studies only twenty-one 
stated telemedicine was effective, eighteen stated it was promising and others raised questions for further 
analysis.  
4.4.1. Behavioral improvements 
Significantly, our results found that every clinical trial showed noteworthy positive behavioral outcomes 
of telemedicine.  The trials conclude that even though telemedicine does not improve medical conditions 
for certain, it does invoke positive behavioral change.  However, the literature urges for further 
investigations due to limited evidence.  In addition, when authors found behavioral improvements, which 
were not the main scope of clinical trial, they mentioned those worth investigating in future to determine 
conclusive results.  Some authors also mentioned the study design was limited.  Table I summarizes the 
effectiveness in terms of physical and behavioral improvements. 
Table I: Effectiveness of clinical trials- physical improvements, behavioral improvements and need for 
further investigation 
Study Physical Improvement Behavioral Improvement Further Investigation 
Needed? 
Rutten et al. 
1990  
Yes - Weight and/or 
glucose.  
Yes.  No - Concluded to be 
effective. 
Shultz et al. 
1991 
Yes - Blood glucose 
level significantly 
dropped.  
Yes - Adherence to dietary 
guidelines and well-being.  
No - Concluded to be very 
effective. 
Meneghini 
et al. 1998  
Yes - Reduced blood 
glucose and frequency of 
consults.  
Yes.  No – Concluded to be 
effective. 
Piette et al. 
2000  
Nil improvement in 
blood. Some 
improvement in weight. 
Yes - Self-management 
and awareness. 
Yes-Effective management 
and behavior but no results for 
improved blood glucose. 
Glasgow 
and Toobert, 
2000  
         No. Yes.  Yes - Effective but further 
studies for a longer period 
required. 
Biermann et 
al. 2000 
No - Same as normal 
treatment. 
Yes - Satisfied with 
lifestyle.  
No - Concluded to be 
effective. 
Tsang et al.  
2001 
Yes - Decrease in blood 
glucose. 
Yes - Dietary behavior 
improvement.  
No - Concluded to be 
effective. 
Mckay et al. 
2002 
No – little improvement 
in blood glucose.  
Yes - Perceived positive 
personal social support.  
Dietary behavior 
improved. 
No - Concluded to be 
effective. 
Cherry et al.  Not mentioned. Yes - Self-management No - Concluded to be 
 The three specific behavioral outcomes to show improvement (Figure 4) are classified as actions, 
changes in awareness about managing type 2 diabetes and satisfaction with the telemedicine healthcare.  
Actions entail activities that the participant adopts due to the technology intervention.  Awareness is the 
2002  and quality of life 
improved.  
effective. 
Montori et 
al. 2002 
No.  Yes - Better self-reporting 
behavior. 
Yes - Further studies needed. 
Izquierdo et 
al. 2003 
Yes - Blood glucose 
reduced. 
Yes.  No - Concluded to be 
effective. 
Young et al. 
2005 
Yes- but not the level 
that authors expected. 
Yes - Lifestyle changes 
and adherence to 
treatment. 
No- Concluded effective for 
Caucasian but urged further 
investigations for other ethnic 
groups. 
Cho et al. 
2006 
Yes - significant 
improvements. 
Yes - Self-management 
improved - attributed to 
the recommendations 
received from medical 
staff. 
No - Concluded to be very 
effective. 
Kim and 
Kim, 2008 
Yes- significant 
improvements. 
Yes - Enthusiasm and 
motivation in self-
management. 
No - Concluded to be very 
effective. 
Bujnowska-
Fedak et al. 
2011 
Yes. Yes - Perceived 
improvement about blood 
glucose, diet and diabetes. 
Improved mental health. 
No - Concluded that only 
patients who are aware of their 
diabetes gain benefits from the 
system. 
Williams et 
al. 2012 
Yes. Yes - Improved adherence 
to self-care and mental 
health improvement. 
No - Concluded to be 
effective. 
Zolfghary et 
al. 2012 
Yes. Significant 
improvements. 
Yes - Patients showed an 
increase in physical 
exercise, diabetic 
medication intake and diet 
adherence. 
No - Concluded to be very 
effective. 
Tang et al. 
2013 
Yes. Yes - Continuous 
engagement was 
demonstrated. 
Yes - further studies needed if 
nurses can maintain this 
Pressman et 
al. 2014 
No. No. Yes - additional studies are 
needed 
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Figure 4: Behavioural improvements of telemedicine on diabetes type 2 patients 
 informed state of mind the participant achieves after using the telemedicine intervention.  Satisfaction 
involves the participants´ satisfaction from using the technology intervention. The nineteen studies 
revealed the following findings of behavioral improvements: 
 Rutten et al. [61] reported overall improvement in personal health care and quality of life for 
all patients.  The participation stimulated the patients to keep closer control of blood glucose 
levels and increased their motivation of maintaining good levels;   
 Shultz et al. [53] showed that using telemedicine helped patients adhere to a dietary plan and 
other healthy habits;  
 Meneghini et al. [67] found patients became an active participant and got involved in 
metabolic control.  Technology-intervened systems empowered case managers to increase 
intervention and improve metabolic control.  In addition, Meneghini et al. [67] have urged 
the importance of the psychological foundation, possible system dependencies, and 
personality traits are contributing factors in the various behaviors that require further study;  
 Piette et al. [65] stated the automated telephone assessment resulted in improved self-care, 
weight monitoring for patients even though the interaction with the nurse was less than six 
minutes per month. It also allowed patients with behavior reinforcement;  
 Glasgow and Toobert [68] found improvements in dietary behavior of the patients. This 
clinical trial is first of its kind to consider social cognitive-environmental model in an 
intervention; 
 Biermann et al. [64] observed that patients were enthusiastic about sending data and 
preferred telemanagement rather than daily logging with pen and book; 
 Montori et al.  [71] work also showed similarly a better way of self-reporting and 
documenting to improve well-being;   
 Izquierdo et al. [73] measured stress levels of diabetes patients through teleconferencing.  
They found patients’ quality of life improved by reducing the diabetes related stress, which 
helped the patients better manage the illness; 
 Cherry et al. [70] showed that overall quality of life was improved, which is evidenced by 
the SF-12 survey, which indicated a change of self-management behavior; 
 McKay et al. [69] showed social support is also important for self-management and 
awareness, where improvements in patients’ perceived availability of social support was 
relative to participants who only had computer access to information about diabetes.  
Connecting with other type 2 diabetes patients helped patients to engage better in self-
management; 
 Tsang et al. [62] reported that dietary awareness was generated after use of the technology; 
 Young et al. [74] published the behavioral outcomes in a companion article and reported 
participants receiving the intervention continued to report high levels of satisfaction with 
their treatment after a year and more than 90% strongly agreed or agreed that the telecarer 
approach was acceptable. Qualitative comments pointed to the importance of a personalized 
service; increased feelings of well-being, including confidence and self-control; help with 
problem-solving; and patients developing rapport and a strong bond with the telecarers [87]. 
 Cho et al. [72] expected a majority of patients’ questions to be about drug dosage during the 
30 month trial.  However, they concluded that the contrary was true because only 20% times 
patients actually sought for glucose dose adjustment of the drug.  Instead, the authors found 
41% of the recommendations made were for patients seeking encouragement and problem 
assessment and 30% of patients asked for some sort of counseling.  
 Kim, Kim [63] attributed the significant physical improvement of patients was due to their 
behavioral changes.  Patients were found to have more contact with caregivers through SMS 
and internet based messages, which improved their enthusiasm, motivation and engagement 
in blood glucose monitoring.  
  Bujnowska-Fedak et al. [80] found that patients who used the system alone benefited with 
an increased quality of life score shown in the surveys that indicates better mental health 
and higher prevention against depression. 
 Zolfaghari et al. [88] found that both SMS and telephone intervention found significant 
improvements in behavior. 
 Tang et al.[89] found physical improvements through behavior change and attributed it to 
the Hawthorne effect, where patients are influenced by awareness of being observed.  The 
authors intended to understand factors that might predict patient engagement.  
The findings on behavioral improvements in this meta-synthesis show positive results in type 2 
diabetes treatments and comply with the diabetes treatment based on diabetes triangle in Figure 1.  The 
compliance is only towards two corners of food and insulin since the technology interventions did not 
have physical activity monitoring functions.  Yet there were awareness of weight management.  
Improvements in dietary behavior and medicine are positive indicators that these telemedicine 
technologies are moving towards patient improvement.  Furthermore, the satisfaction with the technology 
by patients in the trial shows promises for these kinds of interventions.  The behavioral outcomes are 
positive although the medical outcomes in terms of blood glucose are not always positive.  
5. Recommendation for future clinical trials  
A lack of data exists on user (patient) experience with technology-intervened treatments in clinical trials 
of type 2 diabetes, as discussed in section 4.  In-home telemedicine technologies will not serve their 
purpose if they are not adopted by the users.  Information can be collected via the users’ experience and 
interaction to find out reasons that influence effectiveness of telemedicine technologies.  Bardram [76] 
claimed the results of failure to use a technology can be diluted in the end results of a clinical trial.  Early 
evaluations during clinical trials can help technology and medical researchers learn more about user 
experience to identify the positive and negative user interactions. To remediate this situation this paper 
proposes the Clinical User-Experience Evaluation (CUE) method to complement clinical trials in EBP.  
The name CUE was inspired by Bardram’s [76] Clinical Proof-of-Concept (CPOC), which is a prototype 
evaluation phase with a few patients prior to a full-scale clinical trial.  
5.1. The Clinical User-experience Evaluation (CUE) project 
The CUE was conducted in conjunction with a clinical trial of a telemedicine in-home monitoring device 
for type 2 diabetes administered by the Townsville-Mackay Medicare Locals (TMML) in North 
Queensland, Australia.  The TMML trial used a randomised controlled method to explore whether remote 
access to clinical care, supported by telehealth technologies over high speed broadband, leads to 
improved diabetes control [90].  Patients were randomly selected to assign participants to an intervention 
group and to a control group.  The intervention group received additional diabetes care from a care 
coordinator nurse via an in-home broadband communication device that comprises of a tablet computer, 
an automatic glucometer, which is a blood glucose measuring device, and an automatic 
sphygmomanometer, which is a blood pressure measuring device.  The device captures clinical measures, 
provides regular health assessments and videoconference with other health professionals when required 
[90].  
To distinguish the CUE from the TMML randomized clinical trial, the CUE methodology was 
developed as a three stage process: 
1) A contextual inquiry that is performed in-situ in a patient’s home.  During this stage the 
patient uses the device while using the “think-aloud” method as the observer takes notes.  
Then, the observer interviews the patient regarding the process of using the device.  The 
questions are based on the actions that were observed while the patient was using the device.  
This process is conducted during a patient’s regularly scheduled time for using the device. 
2) A semi-structured qualitative inquiry (interview) to understand patients’ experience and 
expectations.  The questions are predominantly developed during stage one.  The interview 
takes place directly after stage one, while perceptions are still fresh in the mind of the user.  
The questions are structured around the patient’s perceived benefits of the device, the 
 patient’s choice of locations, their expectations of the device, their impressions about the 
design of the current device and the patients’ thoughts of how the device should be. 
3) An anonymous survey to encourage free expression without reservations.  During the first 
two stages, the CUE allows for observation of certain behaviour of the participants in 
person.  To verify these observations, an anonymous survey is conducted in the third stage 
to obtain patients’ feedback and opinions on the observations from the previous stages.  This 
survey was administered eight months after stage two to allow for reflection and was 
anonymous to uncover thoughts that may not have emerged in the in-person interviews. 
5.1.1. Implementation of CUE 
The CUE does not interfere nor impede in the traditional clinical trials but is an additional activity that is 
carried out concurrently by non-medical staff.  Table II describes alignment of activities of the clinical 
user evaluation to the activities of the full medical clinical trial. 
Participation in the CUE was voluntary and nine patients were selected based on a subset of 
intervention group within the TMML clinical trial.  The CUE contextual inquiry (stage one ) and the 
qualitative inquiry (stage two) were completed after a three month period from when the patient was 
given the initial training by the nurses on how to use the in-home monitoring device.  This time period 
allowed the patients to become accustomed to the device to ensure the data from the CUE was not 
influenced by the initial novelty or unfamiliarity with the device [92,93].  Two of the nurses who went to 
the patients’ homes during setup of the technology, training with the technology and provided support 
through telephone communication with these patients were also interviewed. 
Table II: Interweaving the CUE within the overarching clinical trial 
Activity/Detail Clinical User-Experience Evaluation Clinical Trial 
Investigation 
aims 
Investigates patients’ perception, understanding, 
feeling and usage of a technology for healthcare. 
Investigates patients’ medical 
condition with an intervention that 
can be a drug or a technology. 
Outcome To provide user feedback about using the trial 
technologies and a guide for future improvement 
of the technology including features that were 
lacking or non-existent that would benefit the 
treatment process.. 
To provide enough evidence for 
medical practitioners to make sound 
judgments. 
Sample size A smaller sample population similar to HCI 
qualitative user evaluation is appropriate [91]. 
Requires large sample population to 
provide substantial and robust 
evidence.  
Time period Conducted at least after three months from the 
start of the clinical trial. Each participant was 
contacted twice.  
Conducted over an extended period 
of time depending on the treatment 
with data collected regularly.  
Regulations There are no HTA regulation limitations. CUE 
is a form of observational interview that tests 
interaction with a device without interfering in 
any medical protocols, there is no physical or 
psychological stress. CUE is conducted at the 
regular times a patient uses the technology as 
part of the overarching clinical trial.  
Rigorous form of testing that must 
follow HTA guidelines. Clinical 
trials often include psycho-social 
analysis questionnaire. 
Investigator Can be carried out by anyone working in the 
field of HCI with simple practice and 
observational skills. 
Carried out by medical staff, or 
caregivers who have either medical 
credentials or training in healthcare 
and/or social work. 
Recruitment Participants come from the clinical trial 
intervention group.  
Larger samples of volunteers are 
sought who have specific medical 
conditions. 
Ethics Privacy of information is required and 
participant must provide written consent.  
Strong regulated ethical process and 
abiding by HTA regulations.  
 5.1.2. Data analysis of the CUE 
All contextual inquiry and qualitative inquiry sessions were audio-recorded, then transcribed.  
Photographs and field notes were taken at the time of the sessions.  The contextual inquiry was analyzed 
to recommend patient-centered system design by following steps from contextual design [94].  The 
qualitative inquiry transcripts were open-coded and themes were developed from patients’ answers.  
NVivo software was used to manage the codes and themes. During the contextual inquiry patients were 
observed while they uploaded their blood glucose and blood pressure.  The patients led each session and 
talked about the device like an instructor while the researcher listened and took notes. 
5.2. Preliminary results from the CUE 
Results from CUE provided deep insights into how patients perceive the device and how to improve the 
device.  
5.2.1. Types of users (patients) 
All patients do not interact with the device the same way.  Individual variations of their interaction were 
noted through CUE. The patients could be grouped as the following:  
 Proactive patients are very proactive and used the technology to upload their regular blood glucose 
and blood pressure regularly.  In addition, the proactive patients also used diabetes awareness 
information that was available on the tablet PC.  
 Accepting patients welcome the use of the technology but did not spend extra time to explore the 
features for diabetes awareness.   
 Indifferent patients use the technology because they are told they have to. They do not resist and do 
not seem to care either way.  
 Resistant patients are opposed to using any technology.  For example, one patient was resistant due 
to their lack of experience in technology use and lack of ownership of a computer or mobile-phone.  
This patient was in the clinical trial intervention group due to the random participation for 
recruitment (i.e., a lottery method).  Notably, although resistant, the patient used the technology 
because they felt they had to commit to the clinical trial.   
5.2.2. Ease of use 
All patients were given training to use the technology by their nurse.  A nurse went to a patient’s home 
during set up and trained the patients for approximately one hour.  The training consisted of 
demonstration by the nurse followed by practice sessions in the presence of the nurse.  Two nurses were 
also available during the rest of the clinical trial to answer questions about problems with the technology.  
In cases when the guidance through phone was unable to resolve the problems, the nurse would visit a 
patient’s home personally or send a technician.  
Two patients were not as comfortable with the technology as the others despite having used the 
devices for more than 13 weeks before participation in the CUE.  One was a patient from technology 
“resistant” group while the other was from the “indifferent” group.  The user types of section 5.2.1 could 
be related to a patient’s ease of use with the technology.  According to the nurses, “What patients describe 
as a problem with the technology is often not what the real problem is”.  The nurses went on to state that 
“often it is a step that the patients forgot but they thought the technology had problems”.   
5.2.3. Other significant results 
The implementation of the CUE during this clinical trial revealed further rich information including:   
 Patients’ perceived benefits;  
 Patients’ future decision to use the technology; 
 Patients’ feedback about the technology [95]; and  
 Recommendations of the technology design  
These results are very detailed and would be reported in future publications.  
 6. Discussion 
Although numerous clinical trials have been conducted that examine the effectiveness of technology-
intervened treatments, the results and conclusions are not absolute.  The business and technology 
communities continue research and development of these treatments.  TechCast [96] performed a study to 
determine the future of medicine to be telemedicine, telehealth and e-health services.  This study found 
the global telemedicine market grew from $9.8 billion USD in 2010 to $11.6 billion USD in 2011 and 
was expected to reach $27.3 billion USD in 2016, which is an additional 15% global rise in adoption.  
Conversely, technology-intervened treatments expect patients to have a more proactive role in 
comparison to the traditional healthcare methods  [97].  Even if patients are provided with the latest state-
of-the-art technology at home, the technology-interventions will not benefit the future healthcare systems 
if they do not use them.  For this reason, research into the technology interventions through a HCI 
perspective is important. 
Benefits of telemedicine could be lost due to the problems faced in the use of the technologies.  
A clinical trial study by Bujnowska-Fedak et al. [80] reported that patients who operated the device by 
themselves gained greater benefits of the medical treatments than those that could not or would not use 
the technology.  The study reported only 35% of patients could use the technology without assistance and 
they gained more benefits from the technology-intervened treatment.   
The importance of user-experience of patients is valuable in a clinical trial. A study by Cho et al. 
[72] reported that during telecare support, the researchers expected a majority of patients’ questions to be 
about drug dosage.  Unexpectedly, the study discovered approximately 80 percent of patients sought 
encouragement and counseling while only 20% of patients sought information on drug dose adjustment.  
This discovery showed the potential telemedicine could have towards patients’ well-being through the 
information dissemination, support and influence.  
Generally, user-centric design for assistive health technologies is carried out on users who are 
not patients due to ethical reasons or strong regulations by HTA.  The inclusion of CUE as a part of an 
overarching clinical trial with real patients in real situations can be beneficial to the design process of 
these technologies because it explores and extracts knowledge on patient perceptions of the technology.    
6.1. Promise of persuasive technology in telemedicine for type 2 
diabetes treatment 
Persuasive technology intervention in telemedicine is beneficial for diseases like type 2 diabetes where 
the only cure is through behavioral management [98].  Diabetes needs strict control of the blood glucose 
level by balancing food, exercise and insulin (or medication) within the diabetes triangle (Figure 1) [14].  
To educate and motivate a change in eating behavior the persuasive techniques would be an initial 
recommendation to inform diabetes patients of good food and food to avoid.  There exists already 
multimedia applications via CD-ROM for diabetes self-management counseling that are educational and 
showed behavior improvements [99].  These applications were simply educational; they could potentially 
be even more effective by employing persuasive technologies.  Motivation and awareness to build better 
habits for exercise and medication could also be accomplished through persuasion.  For example, just-in 
time messages or triggers can be setup with the appropriate device reminders to take insulin injection or 
medication.  
Persuasive in-home monitoring can make the management of blood glucose levels timely and 
provide an efficient day-to-day management of diabetes to prevent complicated stages.  Interventions for 
behavior change has been identified as a major cornerstone for changing dietary behaviors [100].  A US 
study of over 17,000 patients enrolled in a home telehealth program reported a 20 percent reduction in 
hospital admissions and 25 percent reduction in bed days of care for chronic health condition 
management [101].  Recent work has conceptually explored the promises of persuasion techniques if 
added in existing telemedicine type 2 diabetes in-home monitoring interventions [98].  
 6.2. Pervasive technology and telemedicine 
The advent of pervasive technologies (mobile devices, wireless sensor networks) provides a great future 
for telemedicine in general and specifically for chronic diseases like type 2 diabetes. Telemedicine 
through the use of pervasive technologies have the potential to change the paradigm of current healthcare 
models[97,102].   
Two potential challenges may arise.  First, a new technology must show enough clinical 
evidence of improvement of health conditions compared to alternative therapies that have existed before, 
which is challenging and may slow down the use of pervasive technologies in telemedicine and 
healthcare.  Bardram and Mihailidis [102] called this phenomenon the antithesis of the technology-push 
mindset found in consumer technologies. Second, how welcoming/resisting will the doctors and nurses be 
to the new technologies that require changes in the existing healthcare services? 
7. Conclusion 
This paper is a meta-synthesis that systematically reviewed a comprehensive list of clinical trials of 
technology-intervened treatments for the care of type 2 diabetes from HCI perspective. This paper 
identifies patients as the most important focus of technology-intervened treatments.  The meta-synthesis 
determined there is a need for a new method that could capture the experience of users (patients) in a 
clinical trial of technology-intervened treatments for type 2 diabetes.  To satisfy this need, this paper 
describes the CUE, which was developed to complement clinical trials in EBP.  The CUE was 
implemented concurrently in a clinical trial and provided insights about the patients as technology users.  
The objective of this paper was to assess the types of technology applied and their effectiveness 
in technology-intervened treatments, which led to two important conclusions to inform future exploration 
of telemedicine and persuasive technology.  First, the reasons for dropout or withdrawal of patients can 
significantly inform the future development and design of information technology used in technology-
intervened treatments.  Improvements in telemedicine require knowledge and understanding of how users 
(patients) physically and emotionally act and react with the technologies.  However, currently, the reasons 
for withdrawal have not been investigated in clinical trials.  Second, all of the reviewed papers reported 
patients had significant behavioral changes via telemedicine techniques although improvements in the 
physical conditions were not consistent.  The outcomes show the potential of telemedicine in the 
treatment of diseases like type 2 diabetes where the key to success is behavioral change and continuous 
management.   
This paper showed that telemedicine have been effective in providing the education and 
awareness in the patients’ own well-being.  The key to surviving diabetes involves a long-term 
management of the diabetes triangle model, which includes a balanced control of diet and exercise, home 
blood glucose testing and insulin (or medication) if required.  The majority of the studies reviewed 
concluded that telemedicine provided significant health improvements in weight management and blood 
glucose levels.   
In-home technology intervened healthcare such as telemedicine and other pervasive healthcare 
technologies will increase with the demographic shift.  Currently, there is a disjuncture between 
telemedicine and persuasive technology for type 2 diabetes.  The technologies used in the clinical trials 
this paper investigated did not have a persuasive design consideration, yet they had positive behavioral 
changes to affect well-being.  Recent studies suggest that persuasive technology could change behavior in 
patients with in-home technology intervened treatments.  The combination of telemedicine and persuasive 
technology can provide better solutions for type 2 diabetes treatments. 
The full results of CUE project with in-depth analysis will be published in future work.  Both the 
technological and medical reasons for patient withdrawal from clinical trials is important to understand.  
During future trials, researchers are urged to take an approach towards data collection that would include 
patients’ physical and emotional actions/reactions with the technologies.  Future work will conduct 
further investigations of measuring effectiveness and integration of telemedicine technology.   
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 Appendix A: Summarized results of reviewed clinical trials classified by technology type, training or setup issues, participants and dropouts 
Study/Location Participants Type of technology Training/Setup/ 
Maintenance 
Reasons for withdrawals 
Rutten et al. 1990 - 
Netherlands 
149 of 171 eligible type 2 
diabetic patients, 40 to 75 
years 
Handheld portable self-monitored devices Not mentioned 2 withdrawals due to motivation 
Shultz et al. 1991 - 
Vermont USA 
30 Diabetes Mellitus patients 
specific types not specified. 
Glucometer connected to a modem at home. Data 
transfer to medical center for graphical representation to 
reported back to patient 
Patients were given 
verbal instructions.  No 
technical difficulties. 
10 withdrawals, XX due to  unrelated 
medical conditions and the for the 
remaining the reasons were not 
reported 
Meneghini et al. 1998 
-  
Florida USA 
187 type 1 and type 2 
diabetes. 
Patients entered diabetes data on a touch-tone telephone.  
Voice messages on progress were then left for patients. 
Patients received a 15 
minute induction and user 
manual.  No technical 
difficulties.   
77 withdrawals- authors propose to 
question the reason in future  
Piette et al. 2000 - 
California USA 
280 type 2 diabetes. ATDM (Automated telephone disease management) Not mentioned 5 refused follow up. 8 refused data 
collection- reasons not reported 
Glasgow and Toobert, 
2000  Oregon USA 
320 of 419 eligible type 2 
diabetes (76% enrolment). 
Interactive CD ROM program with touch screen 
capability so o the patient could receive immediate 
personalized data 
 43 withdrawals -  reason not reported 
Biermann et al. 2000 
Germany 
46 type 1 and type 2 diabetes. Telephone advice given by clinician in response to 
transmitted blood glucose 
Training via a diabetes 
education program. 
No dropouts reported 
Tsang et al. 2001 - 
China 
20 initial patients. Handheld electronic diary connected to the telephone 
line 
Two weeks training prior 
to the trial.  No technical 
difficulties.   
1 withdrawals- reason not reported 
Mackay et al.2002 - 
Oregon USA 
160 of 265 eligible type 2 
diabetes (61% enrolment) all 
were novice computer users 
Internet based self-management Not mentioned 37 withdrawals- reason not reported 
Cherry et al. 2002 - 
Texas USA 
169 type 1 and type 2 Telemedicine Diabetes Disease Management - A web 
based interface for patient input. 
Not mentioned Withdrawals not reported 
Montori et al. 2002 - 
Minnesota USA 
200  Implemented DEMS   
  
Izquierdo et al. 2003 - 
New York USA 
56 type 2 Personalized teleconferencing to educate patients  1 due to failing consequent 
appointments. 8 due to lack  
of time 
Young et al. 2005 - 
Salford, UK 
 591 type 2 Pro-Active Call Center Treatment Support 
(PACCTS),using trained nonmedical telephonists 
supported by specially designed software and a diabetes 
nurse 
 Not mentioned 83 dropouts with an additional 22 
(5.6%) dropped out for call center 
related reasons (e.g., not being able to 
cope with the number of calls). Other 
dropout reasons included: 4 not happy  
with the advice given, 3 changed their 
minds, 3 due to travelling and 2 were 
too busy. 
Cho et al. 2006- 
Seoul, South Korea 
40 type 2 Web site (www.biodang.com) to upload blood glucose 
and interact with doctors and nurses 
Yes Not reported 
Kim and Kim, 2008-
Seoul, South Korea 
18 type 2 Continuous education and reinforcement of diet, 
exercise,medication adjustment with frequent self-
monitoring of blood glucose levels through SMS on 
mobile phone and internet 
Yes Not reported 
Bujnowska-Fedak et 
al. 2011- Poland 
50 type 2 In home wireless glucose monitor and transmitter and 
transfer through internet 
Yes 3 dropouts 
2 for being disinterested with the 
technology 
Williams et al. 2012- 
Brisbane, Australia 
60 type 2 Automated and interactive telephone system that 
emulates physicians. 
Not mentioned 4 dropouts 
Unable to use the blood glucose 
meter and disappointed with the 
technology 
[88]- Iran 39 SMS type 2, 41 telephone 
type 2  
SMS and telephone conversation in two separate 
interventions. 
Yes 3 dropouts 
[89]-Several states, 
USA 
405 type 2 Palo Alto edical Center’s own online diabetic 
management system that comprises of five components 
of web-based, infrared, reports, teleconsulting, video 
instructions  
Yes 54 dropouts- reasons not reported 
Pressman et al. [103]-
Calinfornia, USA 
118 type 2 Telemonitoring Diary provided by Samsung Yes 9% of the 118 paties dropped out- 
reasons not reported 
 
